|
시장보고서
상품코드
1983213
이비인후과 질환 치료 시장 : 치료법별, 약물별, 기관별, 최종사용자별, 지역별ENT Disorder Treatment Market, By Treatment Type, By Drugs, By Organ Type, By End User, By Geography |
||||||
이비인후과 질환 치료 시장은 2026년에 365억 3,000만 달러로 추정되며, 2033년까지 573억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 6.6%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 365억 3,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 6.60% | 예측 금액(2033년) | 573억 달러 |
이비인후과(ENT)는 귀, 코, 목과 관련된 질환을 다루는 의학의 한 분야입니다. 귀, 목, 코와 관련된 질환은 삶의 질에 큰 영향을 미치며, 만성 편도선염, 귀 감염, 심한 부비동염, 인후두암, 후두암 등 일부 질환의 경우 수술이 필요할 수 있습니다. 이러한 질환을 치료하기 위해서는 이비인후과 치료가 필요합니다. 이러한 질환은 의료기기나 약물을 이용해 치료할 수도 있지만, 심한 경우에는 수술이 권장됩니다. 이비인후과 의사의 권고에 따라 후두암 등 일부의 경우 수술이 필요하며, 종양 전문의가 종양을 절제하는 수술은 종양내과 전문의가 시행하고, 수술 후 중증도에 따라 방사선 치료나 항암화학요법을 시행합니다.
시장 역학
주요 기업들은 연구 부문의 강화, 판매 및 마케팅 측면의 제품 상용화를 위해 제휴 및 인수와 같은 비유기적 성장 전략에 집중하고 있습니다. 예를 들어, 2017년 7월, Entellus Medical은 흡수성 코 임플란트 및 기타 의료기기를 개발, 제조, 판매하는 비상장 이비인후과 의료 기술 기업인 Spirox, Inc.
또한, 2021년 8월에는 의료기술의 세계 리더인 메드트로닉(Medtronic plc.)이 환자 치료의 혁신에 초점을 맞춘 세계 이비인후과(ENT) 의료기술의 리더인 인터섹트 이비인후과(Intersect ENT)와 협약을 체결하였습니다. 이번 계약에 따라 메드트로닉은 주당 28.25달러에 인터섹트ENT의 전 주식을 전액 현금 거래로 인수했으며, 기업 가치는 약 11억 달러에 달합니다. 양사 이사회는 만장일치로 본 거래를 승인했습니다. 메드트로닉의 인터섹트 ENT 인수는 이비인후과 수술에 사용되는 제품 포트폴리오를 확장하는 것입니다. 상호 보완적인 제품 라인과 메드트로닉의 노력으로 만성 부비동염(CRS)을 앓고 있는 환자들에게 긍정적인 영향을 미칠 수 있을 것으로 기대됩니다. 인터섹트ENT의 PROPEL(R) 및 SINUVA(R) 부비동 임플란트는 부비동 통로를 열고 치유를 돕는 항염증 스테로이드를 투여하는 임상적으로 입증된 솔루션입니다. 이 제품들을 메드트로닉의 내비게이션 시스템, 전동 수술기구 및 기존 조직 건강 관련 제품과 결합하여 CRS 환자를 치료하는 외과의사에게 보다 폭넓은 솔루션을 제공하는 것을 목표로 하고 있습니다.
본 보고서의 주요 특징
- 세계의 이비인후과 질환 치료 시장에 대해 조사 분석했으며, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 이비인후과 질환 치료 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 정리했습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 이비인후과 질환 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 이비인후과 질환 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 이비인후과 질환 치료 시장 : 치료법별(2020-2033년)
제5장 세계의 이비인후과 질환 치료 시장 : 기관별(2020-2033년)
제6장 세계의 이비인후과 질환 치료 시장 : 최종사용자별(2020-2033년)
제7장 세계의 이비인후과 질환 치료 시장 : 지역별(2020-2033년), 시장 규모
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고문헌과 분석 방법
KSM 26.04.20Ent Disorder Treatment Market is estimated to be valued at USD 36.53 Bn in 2026 and is expected to reach USD 57.30 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 36.53 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.60% | 2033 Value Projection: | USD 57.30 Bn |
ENT also known as otolaryngology is a stream of medical science that deals with disorders associated with ear, nose, and throat. Diseases related to ears, throat, and nose significantly affect the quality of life and could lead to surgeries in few cases such as chronic tonsillitis, ear infections, and severe sinusitis problems as well as cancers of the throat or larynx, and others. In order to treat these disorders, ENT treatment is required. These diseases can either be treated with the help of devices or drugs, however, surgeries are recommended to patients with severe cases. Surgical procedures are required in few cases such as throat cancer as recommended by otolaryngologist, however, an oncologist performs the tumor removal procedures, which is either followed by a radiation or chemotherapy, depending on the severity.
Market Dynamics
Key players are focusing on inorganic growth strategies such as agreement and acquisitions for enhancement of research department as well as commercialization of products in terms of sales and marketing. For instance, in July 2017, Entellus Medical announced a definitive agreement to acquire Spirox, Inc. a privately held ENT medical technology that develops, manufactures and markets absorbable nasal implants and other medical devices.
Moreover, in August 2021, Medtronic plc., the global leader in medical technology signed agreement with Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic acquired all shares of Intersect ENT for USD28.25 per share in an all-cash transaction implying an enterprise value of approximately USD1.1 billion. The boards of directors of both companies have unanimously approved the transaction. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures. The complementary product lines and Medtronic's efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). Intersect ENT's PROPEL(R) and SINUVA(R) sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing. By combining these products with Medtronic's navigation, powered instruments, and existing tissue health products, the company intends to offer a broader suite of solutions to assist surgeons treating CRS patients.
Key features of the study
- This report provides an in-depth analysis of the global ENT disorder treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ENT disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ENT disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ENT disorder treatment market
Market Segmentation
- Treatment Type Insights (Revenue, USD Bn, 2026 - 2033)
- By Devices
- Hearing Aid Devices
- Voice Prostheses
- Nasal Splints
- Hearing Implants
- Others
- By Drugs
- Antibiotics
- Antihistamines
- Steroids
- Anti-inflammatory Drugs
- Others
- Organ Type Insights (Revenue, USD Bn, 2026 - 2033)
- Ears
- Nose
- Throat
- End User Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital
- Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Sanofi
- AstraZeneca Plc
- Novartis AG
- Pfizer, Inc.
- Mylan N.V.
- Teva Pharmceutical Industries Ltd.
- GlaxoSmithKline Plc
- Otonomy, Inc.
- Merck & Co., Inc.
- Dr. Reddy's Laboratories Ltd.
- Allergen Plc
- Cochlear Ltd.
- Sonova Holdings AG.
- Siemens Healthineers
- Starkey Laboratories, Inc.
- William Demant Holdings, A/S
- Widex A/S
- GN Re/Sound A/S
- Sonic Innovations. Inc.
- Panasonic Corporation
- Beltone
- Rexton Inc.
- Avada Hearing Care
- Miracle-Ear., Inc.
- MED-EL GmBH
- Nuear Hearing Aids, Inc.
- AudioSync, Inc.
- Bernafon
- American Hearing Systems, Inc.
- Unitron Hearing, Inc.
- Zounds, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global ENT Disorder Treatment Market, By Treatment Type
- Global ENT Disorder Treatment Market, By Organ Type
- Global ENT Disorder Treatment Market, By End User
- Global ENT Disorder Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global ENT Disorder Treatment Market, By Treatment Type, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- By Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Segment Trends
- Hearing Aid Devices
- Voice Prostheses
- Nasal Splints
- Hearing Implants
- Others
- By Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Segment Trends
- Antibiotics
- Antihistamines
- Steroids
- Anti-inflammatory Drugs
- Others
5. Global ENT Disorder Treatment Market, By Organ Type, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ears
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Nose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Throat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global ENT Disorder Treatment Market, By End User, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
7. Global ENT Disorder Treatment Market, By Region, 2020 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otonomy, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergen Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cochlear Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sonova Holdings AG.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Siemens Healthineers
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Starkey Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- William Demant Holdings, A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Widex A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GN Re/Sound A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sonic Innovations. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Panasonic Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beltone
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rexton Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Avada Hearing Care
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Miracle-Ear., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MED-EL GmBH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nuear Hearing Aids, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AudioSync, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bernafon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- American Hearing Systems, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Unitron Hearing, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zounds, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
